SI-BONE Inc. Stock News

SI-BONE is pushing higher in revenues and gross profit, clipping another strong quarter. It pulled in 80% gross margin and expects this on a revised FY'23 outlook. Additional fundamental catalysts are

SANTA CLARA, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced

Si-Bone makes the iFuse Implant System for the sacroiliac joint, found in the lower back. The company said it increased its surgeon base to 950 surgeons in the U.S. Revenue for Si-Bone was up 46% year

SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshwari -

Si-Bone (SIBN) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.52 per share a year ago.

SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announce

SANTA CLARA, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announce

SI-BONE, Inc. (NASDAQ:SIBN ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Saqib Iqbal - Director of Investor Relations Laura Francis - Chief Executive Officer Ans

Si-Bone (SIBN) delivered earnings and revenue surprises of 23.81% and 0.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SANTA CLARA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced

SI-BONE, Inc. presents as a niche operator in the surgical intervention of sacroiliac disorders. There are multiple inflection points on the horizon for SI-BONE in FY 2023.

SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshw

Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SANTA CLARA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positi